Autolus Announces Pricing of Public Offering
Autolus Therapeutics plc
LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of its previously announced underwritten public offering in the United States of 75,000,000 American Depositary Shares ("ADSs") representing 75,000,000 ordinary shares at a public offering price of $2.00 per ADS, for total gross proceeds of $150.0 million. All ADSs sold in the offering were offered by Autolus. In addition, Autolus has granted the underwriters a 30-day option to purchase up to an additional 11,250,000 ADSs at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 13, 2022, subject to customary closing conditions.
Jefferies LLC, William Blair & Company L.L.C. and Wells Fargo Securities, LLC are acting as joint bookrunners for the offering.
The securities are being offered pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission ("SEC"). A preliminary prospectus supplement to the prospectus describing the terms of the offering was filed with the SEC on December 8, 2022, and a final prospectus supplement will be filed with the SEC. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement, which, for the avoidance of doubt, will not constitute a "prospectus" for the purposes of the Regulation (EU) 2017/1129 and has not been reviewed by any competent authority in any member state in the European Economic Area. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained for free from the joint book-running managers for the offering, Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com; or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, New York, 10001, at 833-690-2713 or email a request to cmclientsupport@wellsfargo.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
About Autolus
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
This press release contains certain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements with regard to Autolus' expectations regarding the completion of the proposed securities offering. Words such as "anticipates," "believes," "expects," "intends," "projects," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed securities offering discussed above will be consummated on the terms described or at all. Completion of the proposed offering and the terms thereof are subject to numerous factors, many of which are beyond the control of Autolus, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in Autolus' Annual Report on Form 20-F for the year ended December 31, 2021 and other filings Autolus makes with the SEC from time to time. Autolus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Olivia Manser
o.manser@autolus.com
Julia Wilson
j.wilson@autolus.com
Susan A Noonan
S.A. Noonan Communications
susan@sanoonan.com
Ukraine news – live: Kyiv fighting 'for every metre' as France says it's open to sending fighter jets
Europe Dog Dewormers Market is Anticipated to Produce US$ 1,178.20 Million by 2033 | Future Market Insights, Inc.
French warplanes must not be used to 'touch Russian soil', says Macron
Norway's dog dewormers market is expected to develop at a swift rate throughout the forecast period. The United Kingdom is poised to be a major leader in the European market for years to come, with an estimated 14% share projected throughout this period.NEWARK, Del, Jan. 31, 2023 (GLOBE NEWSWIRE) -- The Europe dog dewormers market was estimated to be worth US$ 427.49 million in 2023 and is projected to grow at a CAGR of 10.67% from 2023 to 2033. By 2033, the Europe dog dewormers market to be wor
The Princess of Wales wants the project called Shaping Up to highlight the significance of the formative years of a child's life.
Tyre Nichols death: Three Memphis emergency staff fired
The two paramedics and driver allegedly "failed to conduct an adequate patient assessment of Mr Nichols".
Transfer news live: Arsenal, Chelsea and Premier League clubs eye late deadline day deals
A blueprint is set out to restore nature in England after criticism over pollution and wildlife decline.
Press release: Evolution of the Orange group's Executive Committee
Press release Paris, 31 January 2023 Evolution of the Orange group's Executive Committee The Orange group announces the appointment of Jean-François Fallacher as CEO of Orange France from April 3. He will replace Fabienne Dulac, who after eight years at the helm of Orange France, has chosen to take on new challenges within the Group. Fabienne Dulac will remain on the Executive Committee and will contribute to the deployment of the upcoming strategic plan. Jean-François Fallacher is currently CEO
Most of the world continues to fail to fight corruption with 95 % of countries having made little to no progress since 2017, a closely watched study by an anti-graft organization found Tuesday. Transparency International's 2022 Corruption Perceptions Index, which measures the perception of public sector corruption according to experts and businesspeople, also found that governments hampered by corruption lack the capacity to protect the people, while public discontent is more likely to turn into violence. "The only way out is for states to do the hard work, rooting out corruption at all levels to ensure governments work for all people, not just an elite few," she added.
50 million under winter weather warnings as arctic cold moves in; Texas braces for days of ice: Updates
A swath of the nation from Texas to Ohio and Tennessee was bracing Monday for days of dangerous travel conditions. Elsewhere it was bitter cold.
Pope Francis is opening a six-day visit to Congo and South Sudan on Tuesday, aiming to bring a message of peace to two countries riven by poverty, conflict and what Francis has called a lingering "colonialist mentality" that still considers Africa ripe for exploitation. Aid groups are hoping Francis' trip will shine a spotlight on two of the world's forgotten conflicts and rekindle international attention on some of Africa's worst humanitarian crises, amid donor fatigue and new aid priorities in Ukraine.
The presenter was corrected by co-presenter Susanna Reid and quickly apologised
'One of a kind': US actress Cindy Williams, who starred in Laverne & Shirley, dies at 75
Rosario Dawson is among the actors paying tribute to Cindy Williams
Sunsets and skateboarding: Friends remember Tyre Nichols at Sacramento vigil
Community members and leaders gathered Monday at a vigil for Tyre Nichols, whose death after being beaten by Memphis police has drawn outrage nationwide. Organizers chose to host the remembrance vigil at the Regency Community Skatepark in North Natomas, a place where his childhood friends said they shared a lot of memories together with him.